ReviewHeart failure reviews2022
Left ventricular hypertrophy and sudden cardiac death.
Review in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Machine learning prediction of sudden cardiac death incorporating multiple lipid markers: evidence from the Taiwan Chin Shan community cohort.Lipids in health and disease · 2026Article
- Electrical risk score and electrocardiographic markers in acute cholecystitis: a prospective cross-sectional study using explainable machine learning.BMC cardiovascular disorders · 2026Article
- Predicting Sudden Cardiac Death in Heart Failure with Mildly Reduced/Preserved Left Ventricular Ejection Fraction: A Clinical Review.Journal of clinical medicine · 2026Review
- Biochanin A Mitigates Pressure Overload-Induced Cardiac Hypertrophy Through Modulation of the NF-κB/Cbl-b/NLRP3 Signaling Axis.Cardiovascular drugs and therapy · 2026Article
- A unified multi-task learning framework for automated assessment of left ventricular structure and its systolic function from echocardiography.Scientific reports · 2025Article
- Ejection Fraction Indexed to Left Ventricular Mass and Its Association With Cardiac Event Risk in a Community Population With Mildly Reduced or Preserved Ejection Fraction.Journal of the American Heart Association · 2025Article
- Assessment of left ventricular systolic function and pathological changes using layer-specific strain in rats with myocardial hypertrophy at various disease stages.The international journal of cardiovascular imaging · 2025Article
- Biotechnological Insights into LncRNA-STAT3 Interactions: A Novel Diagnostic Biomarker for Myocardial Hypertrophy.Iranian journal of biotechnology · 2025Article
- 20-HETE mediates Ang II-induced cardiac hypertrophy via ROS and CaScientific reports · 2025Article
- Age and Sex Differences in the Risk of Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy: A Multi-Centre Cohort Study.Vascular health and risk management · 2025Observational
- New clinical application of magnetocardiography: diagnosis of left ventricular hypertrophy.Frontiers in cardiovascular medicine · 2025Article
- Layer-specific proteomic analysis of human hearts in patients with sudden cardiac death.PloS one · 2025Article
- Progress in diagnosis and treatment of hypertension combined with left ventricular hypertrophy.Annals of medicine · 2024Review
- Role of KLF4 and SIAT7A interaction accelerates myocardial hypertrophy induced by Ang II.Journal of cellular and molecular medicine · 2024Article
- Exercise related versus non exercise related out of hospital cardiac arrest - A retrospective single-center study.Resuscitation plus · 2024Article
- Article
- The role of p130Cas/BCAR1 adaptor protein in the pathogenesis of cardiovascular diseases: A literature review.American heart journal plus : cardiology research and practice · 2024Review
- Article
- Reduced DNMT1 levels induce cell apoptosis via upregulation of METTL3 in cardiac hypertrophy.Heliyon · 2024Article
- The Decrease in Estimated Glomerular Filtration Rate as a Risk Factor of Ventricular Tachyarrhythmias after Acute Myocardial Infarction during Hospitalization: A Retrospective Propensity Score Matching Cohort Study.Reviews in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sudden cardiac death (SCD) is among the leading causes of death worldwide, and it remains a public health problem, as it involves young subjects. Current guideline-directed risk stratification for primary prevention is largely based on left ventricular (LV) ejection fraction (LVEF), and preventive strategies such as implantation of a cardiac defibrillator (ICD) are justified only for documented low LVEF (i.e., ≤ 35%). Unfortunately, only a small percentage of primary prevention ICDs, implanted on the basis of a low LVEF, will deliver life-saving therapies on an annual basis. On the other hand, the vast majority of patients that experience SCD have LVEF > 35%, which is clamoring for better understanding of the underlying mechanisms. It is mandatory that additional variables be considered, both independently and in combination with the EF, to improve SCD risk prediction. LV hypertrophy (LVH) is a strong independent risk factor for SCD regardless of the etiology and the severity of symptoms. Concentric and eccentric LV hypertrophy, and even earlier concentric remodeling without hypertrophy, are all associated with increased risk of SCD. In this paper, we summarize the physiology and physiopathology of LVH, review the epidemiological evidence supporting the association between LVH and SCD, briefly discuss the mechanisms linking LVH with SCD, and emphasize the need to evaluate LV geometry as a potential risk stratification tool regardless of the LVEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.